Gastrointestinal Risks and Analgesic Choice

TYLENOL^® does not irritate the stomach the way naproxen sodium or ibuprofen can^1-4

TYLENOL® does not inhibit cyclooxygenase-1 (COX-1), an important enzyme in GI mucosal protection1-5

NSAIDs may increase the risk of GI bleeding in some patients with comorbidities or other risk factors^4,6,7
Aspirin heart therapy and antiplatelet therapy can also increase GI bleeding risks^4,6,7

^{*When used as directed.
†Maximum strength lidocaine without a prescription.}

Watch how NSAIDs’ inhibition of COX-1 can increase GI risk8

Content is restricted by privacy settings. Please review your cookie settings to enable access.

^{*When used as directed.
†Maximum strength lidocaine without a prescription.}

Woman holding a bottle of TYLENOL® PM reading instructions and dosing information.

An appropriate analgesic option

Consider TYLENOL^® for patients at higher risk for GI complications^1-5

VIEW PRODUCT DOSAGE

Package of TYLENOL® Extra Strength Caplets and a #1 Doctor Recommended seal in front of a desk.

TYLENOL® is the #1 doctor-recommended brand of pain reliever

The safety profile and efficacy of acetaminophen are well established

VIEW STUDIES

^{*When used as directed.
†Maximum strength lidocaine without a prescription.}

References

^1.^{Hoftiezer JW, O’Laughlin JC, Ivey KJ. Effects of 24 hours of aspirin, Bufferin, paracetamol and placebo on normal human gastroduodenal mucosa.}^Gut^{. 1982;23(8):692-697.}^2.^{Blot WJ, McLaughlin JK. Over the counter non-steroidal anti-inflammatory drugs and risk of gastrointestinal bleeding.}^{J Epidemiol Biostat}^{. 2000;5(2):137-142.}^3.^{Naproxen. MedlinePlus. Updated March 15, 2022. Accessed March 19, 2023. https://www.nlm.nih.gov/medlineplus/druginfo/meds/a681029.html}^4.^{Frech EJ, Go MF. Treatment and chemoprevention of NSAID-associated gastrointestinal complications.}^{Ther Clin Risk Manag}^{. 2009;5(1):65-73.}^5.^{Data on file. TYLENOL® Professional Product Information. McNeil Consumer Healthcare Division. Fort Washington, PA; 2014.}^6.^{Abraham NS, Hlatky MA, Antman EM, et al; ACCF/ACG/AHA. 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents.}^Circulation^{. 2010;122(24):2619-2633.}^7.^{Kovac SH, Saag KG, Curtis JR, Allison J. Association of health-related quality of life with dual use of prescription and over-the-counter nonsteroidal antiinflammatory drugs.}^{Arthritis Rheum}^{. 2008;59(2):227-233.}^8.^{Bhatt DL, Scheiman J, Abraham NS, et al; American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents.}^Circulation^{. 2008;118(8):1894-1909.}